^
    Apply
    Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in ARID1A Mutated Cancer Focus on Urothelial Carcinoma (RESOLVE) (NCT05154994)
    Phase 1
    University of Utah
    Suspended
    Last update posted :
    02/24/2025
    Initiation :
    01/14/2022
    Primary completion :
    04/01/2025
    Completion :
    11/30/2026
    ARID1A
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Beleodaq (belinostat)
    A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity (NCT06406465)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    02/27/2025
    Primary completion :
    07/30/2027
    Completion :
    07/30/2028
    UGT1A1
    |
    UGT1A1*28 • UGT1A1*1*1 • UGT1A1*28 + UGT1A1*6
    |
    cisplatin • etoposide IV • Beleodaq (belinostat)
    Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (NCT03772925)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/14/2025
    Initiation :
    06/20/2019
    Primary completion :
    06/16/2025
    Completion :
    06/16/2025
    BCL2 • CD4
    |
    TP53 mutation • FLT3 mutation
    |
    pevonedistat (MLN4924) • Beleodaq (belinostat)
    Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics (CHARGE) (NCT04315233)
    Phase 1
    University of Utah
    Recruiting
    Last update posted :
    10/30/2024
    Initiation :
    05/03/2021
    Primary completion :
    04/01/2024
    Completion :
    08/01/2026
    HER-2
    |
    HER-2 negative
    |
    Kisqali (ribociclib) • Beleodaq (belinostat)
    To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL (CRESCENDO) (NCT06072131)
    Phase 3
    Acrotech Biopharma Inc.
    Recruiting
    Last update posted :
    05/27/2024
    Initiation :
    10/04/2023
    Primary completion :
    07/01/2030
    Completion :
    11/01/2030
    ALK • TNFRSF8 • UGT1A1
    |
    TNFRSF8 expression • UGT1A1*1*1
    |
    doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Beleodaq (belinostat) • Folotyn (pralatrexate)
    Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma (ETCTN) (NCT04340843)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/16/2024
    Initiation :
    09/08/2020
    Primary completion :
    01/01/2025
    Completion :
    01/01/2025
    IDH1 • IDH2
    |
    Inqovi (decitabine/cedazuridine) • Beleodaq (belinostat) • guadecitabine (SGI-110)
    Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment (ETCTN 10500) (NCT05627245)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    04/15/2024
    Initiation :
    03/01/2023
    Primary completion :
    03/01/2025
    Completion :
    03/01/2025
    EZH2
    |
    RAS wild-type • EZH2 mutation • EZH2 wild-type
    |
    Tazverik (tazemetostat) • Beleodaq (belinostat)
    Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer (NCT04703920)
    Phase 1
    University of Michigan Rogel Cancer Center
    Recruiting
    Last update posted :
    01/17/2024
    Initiation :
    03/04/2021
    Primary completion :
    07/01/2024
    Completion :
    07/01/2024
    HER-2
    |
    HR positive • HER-2 negative
    |
    Talzenna (talazoparib) • Beleodaq (belinostat)
    Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma (NCT02737046)
    Phase 2
    University of Miami
    Recruiting
    Last update posted :
    01/01/2024
    Initiation :
    12/12/2016
    Primary completion :
    12/31/2024
    Completion :
    12/31/2025
    IFNA1
    |
    Beleodaq (belinostat)
    Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes (NCT02680795)
    Phase 1
    Acrotech Biopharma LLC
    Completed
    Last update posted :
    09/14/2021
    Initiation :
    04/27/2016
    Primary completion :
    07/21/2020
    Completion :
    07/21/2020
    UGT1A1
    |
    UGT1A1*28 • UGT1A1*1*1
    |
    Beleodaq (belinostat)
    Evaluating Safety & Efficacy Belinostat Combo w Nivo Alone & w Ipi in Patients w Treated Metastatic/Advanced Carcinomas w ARID1A Lof Mutation (BENEFIT) (NCT04315155)
    Phase 1
    University of Utah
    Withdrawn
    Last update posted :
    10/28/2020
    Initiation :
    10/01/2020
    Primary completion :
    09/01/2023
    Completion :
    09/01/2025
    ARID1A
    |
    ARID1A mutation
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Beleodaq (belinostat)
    Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin (NCT00993616)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    07/23/2019
    Initiation :
    12/01/2009
    Primary completion :
    07/01/2012
    Completion :
    07/29/2012
    MUC16
    |
    MUC16 elevation
    |
    cisplatin • carboplatin • Beleodaq (belinostat)
    Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL (NCT01686165)
    Phase 2
    University of Arizona
    Completed
    Last update posted :
    08/28/2018
    Initiation :
    08/31/2012
    Primary completion :
    02/09/2016
    Completion :
    11/09/2017
    CD20
    |
    CD20 positive
    |
    Rituxan (rituximab) • Zevalin (ibritumomab tiuxetan) • Beleodaq (belinostat)
    Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors (NCT00413322)
    Phase 1
    Onxeo
    Completed
    Last update posted :
    07/08/2015
    Initiation :
    09/01/2005
    Primary completion :
    03/01/2008
    Completion :
    06/01/2008
    TYMS
    |
    5-fluorouracil • Beleodaq (belinostat)